OverviewSuggest Edit

U.S. Stem Cell is a biotechnology company focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage. The Company's lead product candidate is MyoCell, an innovative clinical therapy designed to populate regions of scar tissue within a patient’s heart with autologous muscle cells, or cells from a patient’s body, for the purpose of improving cardiac function in chronic heart failure patients.

TypePublic
HQSunrise, US
Websiteus-stemcell.com

Latest Updates

Employees (est.) (Dec 2018)10
Revenue (FY, 2018)$6.7 M(+22%)

Key People/Management at U.S. Stem Cell

William P. Murphy

William P. Murphy

Chairman of the Board
Mike Tomás

Mike Tomás

President & CEO
Kristin Comella

Kristin Comella

Chief Science Officer
Show more

U.S. Stem Cell Office Locations

U.S. Stem Cell has an office in Sunrise
Sunrise, US (HQ)
13794 NW 4th St #212
Show all (1)

U.S. Stem Cell Financials and Metrics

U.S. Stem Cell Revenue

Embed Graph
View revenue for all periods
U.S. Stem Cell's revenue was reported to be $6.70 m in FY, 2018
USD

Revenue (Q1, 2019)

1.3m

Gross profit (Q1, 2019)

786.7k

Gross profit margin (Q1, 2019), %

60.1%

Net income (Q1, 2019)

(673.2k)

EBIT (Q1, 2019)

(399.1k)

Market capitalization (8-Oct-2018)

9.5m

Cash (31-Mar-2019)

749.4k
U.S. Stem Cell's current market capitalization is $9.5 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

96.1k2.1m2.2m3.1m5.5m6.7m

Revenue growth, %

2040%7%41%

Cost of goods sold

30.8k844.9k973.0k972.0k1.9m2.1m

Gross profit

65.3k1.2m1.2m2.1m3.6m4.6m
Quarterly
USDQ3, 2013Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019

Revenue

565.3k557.6k710.9k678.2k729.8k1.2m1.4m1.5m1.7m1.8m1.5m1.3m

Cost of goods sold

223.6k243.9k154.4k235.4k332.5k344.6k400.6k482.9k503.8k567.2k544.4k522.1k

Gross profit

341.7k313.7k556.6k442.9k397.3k810.4k985.3k1.0m1.2m1.3m959.5k786.7k

Gross profit Margin, %

60%56%78%65%54%70%71%68%71%69%64%60%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

46.2k36.7k58.4k270.7k986.8k1.4m

Accounts Receivable

19.9k35.0k16.0k43.0k18.0k

Inventories

17.4k42.2k70.4k93.2k

Current Assets

66.9k141.3k115.6k329.0k1.1m1.5m
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(3.1m)(2.3m)(1.6m)(2.1m)(3.5m)(2.2m)

Depreciation and Amortization

2.2k4.5k5.3k5.8k178.7k207.1k

Inventories

63.0k(17.4k)(28.1k)(22.9k)

Accounts Payable

(59.1k)469.2k426.3k
USDY, 2019

Financial Leverage

-0.2 x
Show all financial metrics

U.S. Stem Cell Online and Social Media Presence

Embed Graph

U.S. Stem Cell News and Updates

USRM announces U.S. Stem Cell Clinic Expansion of Products and Services

SUNRISE, Fla., Dec. 6, 2018 /PRNewswire/ -- U.S. Stem Cell, Inc., a leader in regenerative medicine products and services, today announced its three partially owned Florida-based clinics have expanded their menu of services to help meet the growing market demand and patient needs for...

U.S. Stem Cell Blogs

USRM Posts Financial Results for First Quarter 2019

SUNRISE, FL – May 7, 2019 – U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today […]

USRM Chief Science Officer Featured on One Radio Network

SUNRISE, FL – January 15, 2019 – U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today […]

Adipose Stem Cells Demonstrate Effectiveness in Repairing Decubitus Ulcers

Paper Published by USRM Chief Science Officer in Journal of Medical Cases SUNRISE, FL – October 9, 2018 – U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development […]

USRM Chief Science Officer Featured on YourVoice™ America

SUNRISE, FL – October 1, 2018 – U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today […]

CEO Blog: September 2018: An Accomplished Summer

Dear Shareholders and Friends, Thank you for your continued interest and support in U.S. Stem Cell, Inc.’s recent developments and achievements. As we continue to grow, our main focus continues […]

USRM Hires Senior VP of US & International Sales

USRM Hires Senior VP of US & International Sales Former Abbott Pharmaceuticals, Stem Cell Centers Exec Joins Team _________________________________________ SUNRISE, FL – September 11, 2018 – U.S. Stem Cell, Inc. […]
Show more

U.S. Stem Cell Frequently Asked Questions

  • Who are U.S. Stem Cell key executives?

    U.S. Stem Cell's key executives are William P. Murphy, Mike Tomás and Kristin Comella.

  • How many employees does U.S. Stem Cell have?

    U.S. Stem Cell has 10 employees.

  • What is U.S. Stem Cell revenue?

    Latest U.S. Stem Cell annual revenue is $6.7 m.

  • What is U.S. Stem Cell revenue per employee?

    Latest U.S. Stem Cell revenue per employee is $670.1 k.

  • Who are U.S. Stem Cell competitors?

    Competitors of U.S. Stem Cell include Endologix, Pfenex and CEL-SCI.

  • Where is U.S. Stem Cell headquarters?

    U.S. Stem Cell headquarters is located at 13794 NW 4th St #212, Sunrise.

  • Where are U.S. Stem Cell offices?

    U.S. Stem Cell has an office in Sunrise.

  • How many offices does U.S. Stem Cell have?

    U.S. Stem Cell has 1 office.